• Explore /
  • Poster
  • / Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Eric Van Cutsem , Florian Lordick , Peter C. Enzinger , David H. Ilson , Manish A. Shah , Rui-Hua Xu , Sara Lonardi , Kensei Yamaguchi , Yi-Ping Hung , Bozena Kukielka-Budny , Pranob P. Bhattacharya , Maria Matsangou , Ran Li , Diarmuid Martin Moran , Radhika Ranganath , Rupesh Pophale , Jaffer A. Ajani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03504397

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4036)

DOI

10.1200/JCO.2024.42.16_suppl.4036

Abstract #

4036

Poster Bd #

16

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

First Author: Manish A. Shah

First Author: Markus H. Moehler

First Author: Kohei Shitara